Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

Basal Cell Carcinoma Clinical Trial

Official title:

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma in Basal Cell Nevus Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03467789
• Other study ID #: CASE5617
• Status: Recruiting
• Phase: Phase 1
• Start date: October 1, 2018
• Est. completion date: September 1, 2024

Study information

• Verified date: March 2024
• Source: Case Comprehensive Cancer Center
• Contact: Edward V. Maytin, MD, PhD
• Phone: 1-866-223-8100
• Email: TaussigResearch[@]ccf.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to study 50 patients with multiple Basal Cell Carcinoma (BCC) who will be receiving Photodynamic Therapy (PDT) as treatment for their tumors. This study wants to establish the optimal conditions for treating BCC tumors with PDT. Previous research suggests that taking Vitamin D prior to the start of PDT could help improve the effectiveness of the treatment in eliminating the BCC. Overall, this study will help establish oral Vitamin D3/PDT as a new combination therapy for skin cancer (BCC). Photodynamic Therapy (PDT) is an investigational (experimental) technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells. PDT is currently approved for the treatment of BCC in Europe, Canada, and Australia. However, it is experimental in the United States because it is not approved by the Food and Drug Administration (FDA).

Description:

The overall hypothesis is that PDT could provide exceptional benefit in patients with Basal Cell Nevus Syndrome (BCNS) and multiple BCC tumors because PDT is nonmutagenic, nonscarring, and can be safely repeated many times. The specific study hypothesis is that Vitamin D might be useful as a neoadjuvant to improve tumor responses to PDT. In preclinical studies, the investigators showed that epithelial tumors are more responsive to aminolevulinic acid (ALA)-based PDT when "primed" by pre-exposure to the dietary form of Vitamin D (cholecalciferol, D3). This study will test the hypothesis that oral D3 supplements, administered over a relatively short time, can boost the effectiveness of PDT for cutaneous (BCC) in this patient population. Patients with BCNS and multiple BCC, or normal patients with at least 3 BCC tumors, will be enrolled. They will receive three PDT treatments, at two-month intervals, over a 6 month period. Primary Objective • To determine tumor clinical clearance rates after neoadjuvant D3/PDT, and after PDT alone. To accomplish this, the first two PDT treatments in each study patient will be randomized, i.e. one PDT session will be performed after D3 pretreatment, the other without any pretreatment. Secondary Objective(s) - To assess the level of PpIX accumulation in BCC lesions at various treatment visits, in the absence or presence of neoadjuvant D3. (Fluorescence dosimetry measurements) - To assess tolerability of the technique. (Pain scale measurements) - To assess patient satisfaction with the technique. (Cosmetic result, and questionnaire) - To assess D3 serum levels (in serum) and VDR status (in leukocyte DNA), and correlate these results to clinical outcomes. Study Design: In this clinical study, each patient will serve as his or her own control with respect to BCC tumor responsiveness to neoadjuvant D3 supplementation. The first two PDT treatments will be randomized. Thus, patients in Group A will take D3 pills prior to the first PDT treatment, and placebo pills prior to the second PDT treatment. For patients in Group B, the order is reversed. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Patients with VD deficiency will take 14 days of neoadjuvant D3, vs. only 5 days if the initial VD level is normal.

Other known NCT identifiers

• NCT03483441

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 37
• Est. completion date: September 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diagnosis of Basal Cell Nevus Syndrome (BCNS) as defined in the Consensus Statement from the first International colloquium on BCNS.
• Major Criteria are:
• (1) BCC prior to age 20 years, or excessive number of BCCs out of proportion to prior sun exposure and skin type;
• (2) keratocyst of the jaw prior to age 20;
• (3) palmar or plantar pitting;
• (4) lamellar calcification of the falx cerebri;
• (5) medulloblastoma;
• (6) first degree relative with BCNS;
• (7) Patched-1 (PTCH1) gene mutation.
• Minor Criteria are:
• (1) rib anomalies, or other specific skeletal malformations including kyphoscoliosis and short 4th metacarpals;
• (2) macrocephaly;
• (3) cleft/lip or palate;
• (4) fibroma of the heart or ovary;
• (5) ocular abnormalities;
• For diagnosis of BCNS, the participant must have either 2 major criteria, one major and two minor criteria.
• At least three BCC tumors, two of which are biopsy-proven
• Female subjects must not become pregnant during the study
• Subjects must be able to understand and willing to sign a written informed consent document

Exclusion Criteria:

• Pregnant or nursing.
• At risk for hypercalcemia (renal disease, sarcoidosis, etc.)
• Taking vismodegib or a hedgehog pathway inhibitor; must stop at least 3 months prior to visit 1.
• Taking any topical treatment on their BCC tumors; must stop at least 1 month prior.
• Taking Vitamin D or multivitamin supplements; must stop at least 1 month prior.
• Currently undergoing treatment for other cancers with medical or radiation therapy.
• Participants with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material.
• Participants with history of a photosensitivity disease, such as porphyria cutanea tarda.
• Currently participating in another clinical trial.

Related Conditions & MeSH terms

• Basal Cell Carcinoma
• Basal Cell Nevus Syndrome
• Carcinoma
• Carcinoma, Basal Cell
• Syndrome

Intervention

Drug:
• Dietary Vitamin D3 pre-treatment
The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is < 31 ng/mL, and 5 days if the D3 level is > 31 ng/mL

Radiation:
• Photodynamic therapy
Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.

Drug:
• Serum Maintenance Vitamin D3
2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.

Locations

Country	Name	City	State
United States	Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center	Cleveland	Ohio
United States	Medical Dermatology Specialists Phoenix	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BCC: Rate of tumor clearance	Change in tumor diameter per month. For each participant, the investigators will analyze the difference in tumor clearance between treatments, one with neoadjuvant D3+PDT, the other with PDT alone, and the other with or without D3 in order to establish a D3 replete state. The order of the first two treatments is randomized in case the assumption of a linear tumor clearance rate is incorrect; The statistical significance of the difference in Delta-T after D3+PDT versus the difference in Delta-T after PDT alone will be tested using ANOVA.	Up to 6 months after first treatment visit
Secondary	BCC: Level of protoporphyrin IX (PpIX) accumulation in BCC lesions	For each patient, whether in the absence or presence of neoadjuvant Vitamin D3, assessments of PpIX accumulation in BCC lesions using fluorescence dosimetry measurements will be made at selected treatment visits.	Up to 6 months after first treatment visit
Secondary	Serum 25-hydroxy-vitamin D3 (25OH-D3) levels	Using a 10mL blood sample, a 25OH-D3 assay will be used to determine D3 levels in the blood	Up to 6 months after first treatment visit
Secondary	Number of patients with active form of leukocyte DNA vitamin D Receptor (VDR)	Study team will collect patients' leukocyte DNA and examine the VDR gene sequences directly. Patients with the active VDR allele are postulated to have better PDT outcomes	Up to 6 months after first treatment visit
Secondary	Pain scale measurement	average pain scale measurements to assess tolerability of the technique to be taken in the week following each PDT treatment (3 total). Ranging from 0 to 10 where 0 indicates no pain and 10 indicates the worst pain possible	Up to 6 months after first treatment visit
Secondary	Erythema score	A measure of Patient Satisfaction Score. Score from photographs on a scale from 1-4 with higher scores indicating more erythema	Up to 6 months after first treatment visit
Secondary	Satisfaction with treatment outcome from the technique	A participant satisfaction questionnaire will be administered at the final study visit measuring the participant's satisfaction with the treatment outcome on a 5 point scale (Extremely Satisfied to Extremely Dissatisfied)	Up to 6 months after first treatment visit
Secondary	Satisfaction with cosmetic outcome from the technique	A participant satisfaction questionnaire will be administered at the final study visit measuring the participant's satisfaction with the cosmetic outcome on a 5 point scale (Extremely Satisfied to Extremely Dissatisfied)	Up to 6 months after first treatment visit